IMUGENE CHART. TA only, page-36890

if you wish to have a closer look at the RAC CEO remuneration (another poster has kindly shared the RAC CEO ASX announcement), you will see evidence that:

1. he opted to take half his CEO salary in way out of the money options with exercise price above ATH sp showing alignment with every single shareholder who bought RAC shares in the past (not just the recent buyers in the lows). He may have even wanted 100% options package but the board didn’t agree … but don’t quote me on that.
2. Over past couple of years he has spent more money buying more shares on market and exercising his options than his cash salary from RAC. Meaning he has put in more money into RAC as a shareholder than he has taken out as an employee.
3. he has never sold a single share since his involvement in RAC (not even to pay for tax commitments which is the often cited excuse for insiders to sell)
4. he was a shareholder and outside investor in RAC before he was invited as a board member and exec. And therefore has the ultimate investor mindset in managing RAC.
5. he is now over 10% shareholder of RAC … bought mainly on market or cap raises.
6. I won’t be surprised to see a director notice of further on market purchases (by CEO and other directors) this year when RAC comes off company trading black out.
7. he has publicly commented that RAC is one and done for him being a executive in listed biotech. He was essentially retired when he invested in RAC and he said he looks forward to getting back to retirement after RAC. He has no aspirations to continue to collect exec pay from the biotechs industry.

If you know a better shareholder aligned ASX listed biotech CEO, please share this with us as I would like to do my diligence on that stock for a potential investment.